Table 1 Patient characteristics of patients who completed all planned procedures. Chi-square and one-way ANOVA was performed for categorical and continuous variables, respectively
From: Optimization of PET protocol and interrater reliability of 18F-PSMA-11 imaging of prostate cancer
2.0 ± 0.2 MBq/kg with furosemide | 2.0 ± 0.2 MBq/kg without furosemide | 4.0 ± 0.4 MBq/kg with furosemide | ||
|---|---|---|---|---|
Number of patients | 21 | 21 | 20 | |
Age (median, Q1–Q3) | 71 (65–74) | 70.5 (63.5–77.25) | 69 (63–74) | F(2,59) = 0.149, p = 0.862 |
Weight (mean ± SD) | 85.1 ± 14.4 | 80.9 ± 10.9 | 81.5 ± 11.9 | F(2,59) = 0.691, p = 0.505 |
Staging | Χ2(2, N = 62) = 6.6633, p = 0.03573 | |||
Initial staging | 0/21 | 6/21 | 4/20 | |
Restaging | 21/21 | 15/21 | 16/20 | |
PSA (ng/mL) (mean ± SD) | 6.90 ± 9.89 | 9.22 ± 18.38 | 7.35 ± 10.96 | F(2,59) = 0.161, p = 0.851 |
Gleason score | Χ2(4, N = 62) = 2.8402, p = 0.5849 | |||
≤ 7 | 8/21 | 8/21 | 9/20 | |
8 | 4/21 | 8/21 | 5/20 | |
≥ 9 | 9/21 | 5/21 | 6/20 | |
Previous treatment | Χ2(8, N = 62) = 6.7322, p = 0.5658 | |||
Prostatectomy | ||||
Salvage therapy | 13/21 | 12/21 | 10/20 | |
Definitive | 13/21 | 9/21 | 5/20 | |
Radiotherapy | 6/21 | 3/21 | 7/20 | |
Current ADT | 8/21 | 3/21 | 2/20 | |
Chemotherapy | 1/21 | 1/21 | 0/20 | |